BAFF Antibody [Buffy-2]

CAT:
223-XA-1012
Size:
0.1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
BAFF Antibody [Buffy-2] - image 1

BAFF Antibody [Buffy-2]

  • NCBI Gene ID:

    10673
  • Swiss Prot:

    Q9Y275
  • Host:

    Rat
  • Reactivity:

    Human, Mouse
  • Immunogen:

    BAFF (monoclonal Buffy-2) antibody was raised against recombinant human soluble BAFF (aa. 83-285) .
  • Clonality:

    Monoclonal
  • Clone:

    Buffy-2
  • Conjugation:

    Unconjugated
  • Type:

    Primary Antibodies
  • Field of Research:

    Chemokines & Cytokines, Cancer
  • Purification:

    Anti BAFF (monoclonal Buffy-2) antibody was purified to ≥95% in SDS-PAGE.
  • Concentration:

    Batch dependent
  • Buffer:

    PBS containing 0.02% sodium azide
  • Modification:

    None
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    BAFF antibody can be stored at 4˚ C, stable for one year.
  • Fragment:

    IgM
  • Applications Notes:

    BAFF antibody can be used to recognize membrane-bound and soluble human and mouse (weak) BAFF by Flow Cytometry, Immunohistochemistry (frozen sections, paraffin sections) and Western Blot. Method: HEK 293T cells (5 x 105) were mock transfected (thin line) or transfected with an expression plasmid enabling surface expression of full length hBAFF (thick line) . Cells were incubated on ice for 30min in 50 μ l FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) containing 1 μ g/mL of MAb to BAFF (Buffy-2) (FITC) . After washing, cells were analyzed by flow cytometry. Method: Tissues are in paraffin sections. Sections are de-waxed and rehydrated, then cooked. Sections are stained in wet boxes, rehydrated and finally prepared as coverslip slides using Eukitt solution. Please inquire for complete protocol..
  • NCBI Official Name:

    Tumor necrosis factor (ligand) superfamily, member 13b
  • NCBI Organism:

    Homo sapiens
  • Background Reference 01:

    Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome: J. Groom, et al.; J. Clin. Invest. 109, 59 (2002) .
  • Background Reference 02:

    Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival: A. J. Novak, et al.; Blood 103, 689 (2004) .
  • Background Reference 03:

    Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL: B. He, et al.; J. Immunol. 172, 3268 (2004) .
  • Background Reference 04:

    BAFF production by antigen-presenting cells provides T cell co-stimulation: B. Huard, et al.; Int. Immunol. 16, 467 (2004) .
  • Tested Applications:

    WB, IHC, Flow
  • Physical Properties:

    Liquid